{
    "2020-06-07": [
        [
            {
                "time": "",
                "original_text": "国内首个新型冠状病毒治疗抗体临床获批 微生物所合作方智飞生物受益几何？",
                "features": {
                    "keywords": [
                        "新型冠状病毒",
                        "治疗抗体",
                        "临床获批",
                        "微生物所",
                        "智飞生物"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}